GLP-1s and Metabolic Health After 50
A practical, evidence-led guide to GLP-1s for weight loss after 50: choosing a drug, getting it and paying for it, holding onto your muscle, and what is coming next. I take tirzepatide myself and write from patient experience, with links to the evidence.
By Gunnar · Patient experience, not medical advice · Updated July 2026

Study details and sources
| Drug | Trial | Dose | Weeks | Weight loss |
|---|---|---|---|---|
| Retatrutide (in trials) | TRIUMPH-1 | 12 mg | 80 | 28% |
| CagriSema (filed) | REDEFINE 1 | 2.4/2.4 mg | 68 | 23% |
| Tirzepatide (Zepbound) | SURMOUNT-1 | 15 mg | 72 | 22% |
| Semaglutide (Wegovy HD) | STEP UP | 7.2 mg | 72 | 21% |
| Orforglipron (Foundayo) | ATTAIN-1 | 17.2 mg tablet | 72 | 12% |
What men over 50 should know
Who they’re for. These are prescription treatments for obesity, or for being overweight with a related health problem, not casual cosmetic weight loss. At their top doses the strongest approved injections now average around 20 percent of body weight in trials, and the pills generally do less. Those are averages, not promises, and the chart above is a useful map of the field, not a ranking. What gets lost is that the benefit is not only the scale. Across trials, these drugs improved blood sugar and blood pressure; some reduced sleep-apnea severity, and semaglutide reduced major cardiovascular events in people with established cardiovascular disease. That is why I file them under metabolic health, not just weight loss.
Muscle and side effects. How much of the loss is fat depends on what you do while it comes off. Large weight losses can include lean tissue, so strength training and adequate protein help preserve muscle, strength, and function. Tolerance varies just as much. Some people barely notice the drug, others fight nausea and constipation for weeks, and the dose climbs slowly for a reason. Someone else’s experience does not predict yours.
Long-term treatment and cost. This is usually a long-term drug: stop, and the weight tends to return, because the biology that made you heavy is still there, so plan for staying on or for a real maintenance plan. And which drug you actually end up on is often decided by your insurance and your budget rather than by the chart, which is what the cost and access section below is for.
Start here
- The 170-Pound Rebuild
How I lost 170 pounds after 50, and what actually kept it off. - Tirzepatide vs Semaglutide: Which One?
The two leaders are now closely matched on weight; semaglutide has the longer heart-outcomes record. - Why I Take a Diabetes Drug and Never Had Diabetes
What these drugs actually are, and who they are for. - How Americans Actually Get Zepbound
The five ways people get it, and the catch with each one.
Access & Cost
- Zepbound and Foundayo on Medicare for $50
How to qualify for the new $50 Medicare copay. - Zepbound vs Grey-Market Tirzepatide
When the brand-name shot is actually the cheaper one. - 45 of 49 Online Sellers Said Yes
A Yale team asked 49 online pharmacies for the drug. Almost all said yes. - Foundayo vs the Wegovy Pill
Eli Lilly’s Foundayo and Novo’s Wegovy pill, the first two GLP-1s you swallow.
Muscle & Recomposition
- What the GLP-1 Muscle-Loss Headlines Get Wrong
The muscle-loss fear pushed me into the gym. Lift, but do not panic. - Body Recomposition After 50
44 pounds of fat off and 9 pounds of muscle on, at the same time. - Apitegromab, the Muscle Shot
A new drug meant to protect your muscle on a GLP-1. Does it keep you strong? - Should You Get a DEXA Scan?
The body scan that shows whether you are losing fat or muscle.
The Pipeline
- Brenipatide vs Tirzepatide
Same class, but Lilly’s new brenipatide is aimed at alcohol and addiction, not weight loss. - Retatrutide: The Biggest Numbers Yet
The triple-hormone shot posting the largest weight loss in trials. - The First Oral GLP-1 Clears the FDA
Eli Lilly’s once-a-day Foundayo pill wins approval. What it means. - Can You Lower Your Dose After Goal?
Once you hit your target weight, can you cut back? The trial finally ran.
Latest in GLP-1s
-

Retatrutide Cost: No Price Yet, and My Estimate Is $450 to $650 a Month
I paid Lilly’s self-pay price for Zepbound for months, and retatrutide has no announced price yet, so here is what…
-

Does CagriSema Have a Brand Name Yet?
CagriSema has no announced brand name as of September 4, 2026. Novo Nordisk owns eleven invented names it could use,…
-

Is CagriSema Covered by Medicare? Not Yet, and Here Is What Would Change That
CagriSema is not approved, so Medicare does not cover it. Here are the three routes after the FDA decides: the…
-

CagriSema vs Zepbound: The New Combo Couldn’t Prove It Matches the Drug I’m On
Novo’s own head-to-head could not show CagriSema was as good as tirzepatide. I take Zepbound myself, and I go through…
-

Does Retatrutide Have a Brand Name Yet?
Retatrutide still has no brand name. But Lilly filed 20 new trademarks in a month and 19 are built on…
-

Retatrutide vs Zepbound: Is Lilly’s Next Weight-Loss Shot Worth Waiting For?
Retatrutide beat Zepbound’s numbers in its own trials, and it did not need its top dose to do it. I…
-

Mounjaro Just Got a Heart Indication. The Trial Behind It Didn’t Beat the Older Drug.
The FDA approved Mounjaro today to lower the risk of heart attack, stroke, and cardiovascular death in adults with type…
-

Sam Sulek’s NewBioRx Sells “Research Only” Retatrutide. A NewBioRx-Branded Site Showed You How to Inject It, Until This Weekend.
Sam Sulek’s peptide company sold retatrutide in a pre-filled pen “for research use only,” while a site under the same…
